Affinity Asset Advisors’s Protagonist Therapeutics PTGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $24.3M | Buy |
440,000
+40,000
| +10% | +$2.21M | 3.32% | 9 |
|
|
2025
Q1 | $19.3M | Buy |
400,000
+270,000
| +208% | +$13.1M | 1.85% | 10 |
|
|
2024
Q4 | $5.02M | Buy |
+130,000
| New | +$5.02M | 0.67% | 34 |
|
|
2024
Q2 | – | Sell |
-100,000
| Closed | -$2.89M | – | 104 |
|
|
2024
Q1 | $2.89M | Buy |
+100,000
| New | +$2.89M | 0.36% | 55 |
|
|
2022
Q2 | – | Sell |
-300,000
| Closed | -$7.1M | – | 57 |
|
|
2022
Q1 | $7.1M | Buy |
300,000
+58,881
| +24% | +$1.39M | 1.14% | 13 |
|
|
2021
Q4 | $8.25M | Buy |
+241,119
| New | +$8.25M | 2.99% | 8 |
|
|
2021
Q3 | – | Sell |
-140,100
| Closed | -$6.29M | – | 83 |
|
|
2021
Q2 | $6.29M | Buy |
140,100
+90,100
| +180% | +$4.04M | 2.25% | 10 |
|
|
2021
Q1 | $1.3M | Buy |
+50,000
| New | +$1.3M | 0.44% | 36 |
|